BrightSpring Health Services (NASDAQ:BTSG) versus Sera Prognostics (NASDAQ:SERA) Head to Head Review

BrightSpring Health Services (NASDAQ:BTSG) and Sera Prognostics (NASDAQ:SERA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares BrightSpring Health Services and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	0.55%	9.29%	2.64%
Sera Prognostics	-30,306.48%	-45.86%	-34.31%

Institutional & Insider Ownership

54.6% of Sera Prognostics shares are owned by institutional investors. 3.4% of BrightSpring Health Services shares are owned by company insiders. Comparatively, 13.5% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares BrightSpring Health Services and Sera Prognostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.57 billion	0.41	-$18.06 million	$0.31	92.74
Sera Prognostics	$108,000.00	1,091.82	-$32.90 million	($0.85)	-3.68

BrightSpring Health Services has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BrightSpring Health Services has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for BrightSpring Health Services and Sera Prognostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0	1	9	0	2.90
Sera Prognostics	0	0	0	0	0.00

BrightSpring Health Services presently has a consensus target price of $29.13, suggesting a potential upside of 1.30%. Given BrightSpring Health Services’ stronger consensus rating and higher probable upside, research analysts clearly believe BrightSpring Health Services is more favorable than Sera Prognostics.

Summary

BrightSpring Health Services beats Sera Prognostics on 11 of the 14 factors compared between the two stocks.

About BrightSpring Health Services

BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.